{"id":190,"date":"2019-10-17T22:19:06","date_gmt":"2019-10-18T02:19:06","guid":{"rendered":"https:\/\/opentextbc.ca\/nursingpharmacology\/chapter\/4-12-beta-1-agonist\/"},"modified":"2023-01-10T17:18:45","modified_gmt":"2023-01-10T22:18:45","slug":"4-12-beta-1-agonist","status":"publish","type":"chapter","link":"https:\/\/opentextbc.ca\/nursingpharmacology\/chapter\/4-12-beta-1-agonist\/","title":{"raw":"4.12 Beta-1 Agonists","rendered":"4.12 Beta-1 Agonists"},"content":{"raw":"Dobutamine is a Beta-1 agonist.\r\n\r\n<strong>Mechanism of Action:<\/strong>\u00a0 Dobutamine stimulates Beta-1 receptors to increase heart rate, force of contraction, and conduction velocity.\r\n\r\n<strong>Indications for Use:<\/strong> Dobutamine is used to treat cardiogenic shock and severe heart failure to increase contractility and cardiac output.\r\n\r\n<strong>Nursing Considerations Across the Lifespan:<\/strong> Beta-1 agonists can safely be administered to pediatric clients, but doses must be adjusted according to weight. These medications are also safe in the older adult population, with no special dose adjustments for renal or liver insufficiency. Beta-1 agonists should not be given in pregnancy, if they can be avoided.\r\n\r\nIn IV administration, dilute concentration before administering. Continuously monitor electrocardiogram (ECG), blood pressure, cardiac output, and urine output during therapy. This drug can cause a marked increase in heart rate and blood pressure. Report all adverse reactions promptly, especially laboured breathing, angina, palpitations, and dizziness.\r\n\r\n<strong>Patient Teaching &amp; Education: <\/strong>The client should be instructed to inform the nurse immediately if they notice chest pain, shortness of breath, or numbness or tingling in the extremities.[footnote]uCentral from Unbound Medicine. <a href=\"https:\/\/www.unboundmedicine.com\/ucentral\" rel=\"noopener noreferrer\">https:\/\/www.unboundmedicine.com\/ucentral<\/a>[\/footnote]\r\n<h1>Dobutamine Medication Card<\/h1>\r\nNow let's take a closer look at the\u00a0 medication card for dobutamine.[footnote]This work is a derivative of <a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/\" rel=\"noopener noreferrer\">Daily Med<\/a> by <a href=\"https:\/\/www.nlm.nih.gov\/\" rel=\"noopener noreferrer\">U.S. National Library of Medicine<\/a> in the <a class=\"internal\" href=\"https:\/\/creativecommons.org\/share-your-work\/public-domain\/\" rel=\"noopener noreferrer\">public domain<\/a>.[\/footnote][footnote]UpToDate (2021). <em>Dobutamine<\/em>. <a href=\"https:\/\/www.uptodate.com\/contents\/search\">https:\/\/www.uptodate.com\/contents\/search<\/a>[\/footnote] Because information about medication is constantly changing, nurses should always consult evidence-based resources to review current recommendations before administering specific medication.\r\n<div class=\"textbox textbox--learning-objectives\"><header class=\"textbox__header\">\r\n<h2 class=\"textbox__title\">Medication Card 4.12.1: Dobutamine<\/h2>\r\n<\/header>\r\n<div class=\"textbox__content\">\r\n\r\n<strong>Class:<\/strong> Beta-1 Agonist\r\n\r\n<strong>Prototypes:<\/strong> Dobutamine\r\n<h3>Therapeutic Effects<\/h3>\r\n<ul>\r\n \t<li>Increases heart rate, force of heart contraction, and speed of conduction between SA to AV nodes<\/li>\r\n<\/ul>\r\n<h3>Administration<\/h3>\r\n<ul>\r\n \t<li>IV only<\/li>\r\n \t<li>Must be administered with infusion device<\/li>\r\n \t<li>Following IV administration, the onset of action of dobutamine occurs within 2 minutes. Peak plasma concentrations of the drug and peak effects occur within 10 minutes after initiation of an IV infusion.<\/li>\r\n \t<li>Continuously monitor ECG, blood pressure, cardiac output, and urine output during therapy<\/li>\r\n<\/ul>\r\n<h3>Indications<\/h3>\r\n<ul>\r\n \t<li>treat cardiogenic shock and severe heart failure to increase contractility and cardiac output<\/li>\r\n<\/ul>\r\n<h3>Side Effects<\/h3>\r\n<ul>\r\n \t<li>marked increase in heart rate and blood pressure<\/li>\r\n \t<li>headache<\/li>\r\n \t<li>nausea<\/li>\r\n \t<li>dyspnea<\/li>\r\n<\/ul>\r\n<h3>Nursing Considerations<\/h3>\r\n<ul>\r\n \t<li>Report all adverse reactions promptly, especially labored breathing, angina, palpitations, and dizziness<\/li>\r\n \t<li>monitor vital signs closely (client must be on continuous ECG monitoring)<\/li>\r\n<\/ul>\r\n<\/div>\r\n<\/div>","rendered":"<p>Dobutamine is a Beta-1 agonist.<\/p>\n<p><strong>Mechanism of Action:<\/strong>\u00a0 Dobutamine stimulates Beta-1 receptors to increase heart rate, force of contraction, and conduction velocity.<\/p>\n<p><strong>Indications for Use:<\/strong> Dobutamine is used to treat cardiogenic shock and severe heart failure to increase contractility and cardiac output.<\/p>\n<p><strong>Nursing Considerations Across the Lifespan:<\/strong> Beta-1 agonists can safely be administered to pediatric clients, but doses must be adjusted according to weight. These medications are also safe in the older adult population, with no special dose adjustments for renal or liver insufficiency. Beta-1 agonists should not be given in pregnancy, if they can be avoided.<\/p>\n<p>In IV administration, dilute concentration before administering. Continuously monitor electrocardiogram (ECG), blood pressure, cardiac output, and urine output during therapy. This drug can cause a marked increase in heart rate and blood pressure. Report all adverse reactions promptly, especially laboured breathing, angina, palpitations, and dizziness.<\/p>\n<p><strong>Patient Teaching &amp; Education: <\/strong>The client should be instructed to inform the nurse immediately if they notice chest pain, shortness of breath, or numbness or tingling in the extremities.<a class=\"footnote\" title=\"uCentral from Unbound Medicine. https:\/\/www.unboundmedicine.com\/ucentral\" id=\"return-footnote-190-1\" href=\"#footnote-190-1\" aria-label=\"Footnote 1\"><sup class=\"footnote\">[1]<\/sup><\/a><\/p>\n<h1>Dobutamine Medication Card<\/h1>\n<p>Now let&#8217;s take a closer look at the\u00a0 medication card for dobutamine.<a class=\"footnote\" title=\"This work is a derivative of Daily Med by U.S. National Library of Medicine in the public domain.\" id=\"return-footnote-190-2\" href=\"#footnote-190-2\" aria-label=\"Footnote 2\"><sup class=\"footnote\">[2]<\/sup><\/a><a class=\"footnote\" title=\"UpToDate (2021). Dobutamine. https:\/\/www.uptodate.com\/contents\/search\" id=\"return-footnote-190-3\" href=\"#footnote-190-3\" aria-label=\"Footnote 3\"><sup class=\"footnote\">[3]<\/sup><\/a> Because information about medication is constantly changing, nurses should always consult evidence-based resources to review current recommendations before administering specific medication.<\/p>\n<div class=\"textbox textbox--learning-objectives\">\n<header class=\"textbox__header\">\n<h2 class=\"textbox__title\">Medication Card 4.12.1: Dobutamine<\/h2>\n<\/header>\n<div class=\"textbox__content\">\n<p><strong>Class:<\/strong> Beta-1 Agonist<\/p>\n<p><strong>Prototypes:<\/strong> Dobutamine<\/p>\n<h3>Therapeutic Effects<\/h3>\n<ul>\n<li>Increases heart rate, force of heart contraction, and speed of conduction between SA to AV nodes<\/li>\n<\/ul>\n<h3>Administration<\/h3>\n<ul>\n<li>IV only<\/li>\n<li>Must be administered with infusion device<\/li>\n<li>Following IV administration, the onset of action of dobutamine occurs within 2 minutes. Peak plasma concentrations of the drug and peak effects occur within 10 minutes after initiation of an IV infusion.<\/li>\n<li>Continuously monitor ECG, blood pressure, cardiac output, and urine output during therapy<\/li>\n<\/ul>\n<h3>Indications<\/h3>\n<ul>\n<li>treat cardiogenic shock and severe heart failure to increase contractility and cardiac output<\/li>\n<\/ul>\n<h3>Side Effects<\/h3>\n<ul>\n<li>marked increase in heart rate and blood pressure<\/li>\n<li>headache<\/li>\n<li>nausea<\/li>\n<li>dyspnea<\/li>\n<\/ul>\n<h3>Nursing Considerations<\/h3>\n<ul>\n<li>Report all adverse reactions promptly, especially labored breathing, angina, palpitations, and dizziness<\/li>\n<li>monitor vital signs closely (client must be on continuous ECG monitoring)<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<hr class=\"before-footnotes clear\" \/><div class=\"footnotes\"><ol><li id=\"footnote-190-1\">uCentral from Unbound Medicine. <a href=\"https:\/\/www.unboundmedicine.com\/ucentral\" rel=\"noopener noreferrer\">https:\/\/www.unboundmedicine.com\/ucentral<\/a> <a href=\"#return-footnote-190-1\" class=\"return-footnote\" aria-label=\"Return to footnote 1\">&crarr;<\/a><\/li><li id=\"footnote-190-2\">This work is a derivative of <a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/\" rel=\"noopener noreferrer\">Daily Med<\/a> by <a href=\"https:\/\/www.nlm.nih.gov\/\" rel=\"noopener noreferrer\">U.S. National Library of Medicine<\/a> in the <a class=\"internal\" href=\"https:\/\/creativecommons.org\/share-your-work\/public-domain\/\" rel=\"noopener noreferrer\">public domain<\/a>. <a href=\"#return-footnote-190-2\" class=\"return-footnote\" aria-label=\"Return to footnote 2\">&crarr;<\/a><\/li><li id=\"footnote-190-3\">UpToDate (2021). <em>Dobutamine<\/em>. <a href=\"https:\/\/www.uptodate.com\/contents\/search\">https:\/\/www.uptodate.com\/contents\/search<\/a> <a href=\"#return-footnote-190-3\" class=\"return-footnote\" aria-label=\"Return to footnote 3\">&crarr;<\/a><\/li><\/ol><\/div>","protected":false},"author":90,"menu_order":12,"template":"","meta":{"pb_show_title":"on","pb_short_title":"","pb_subtitle":"","pb_authors":[],"pb_section_license":""},"chapter-type":[50],"contributor":[],"license":[],"class_list":["post-190","chapter","type-chapter","status-publish","hentry","chapter-type-numberless"],"part":150,"_links":{"self":[{"href":"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-json\/pressbooks\/v2\/chapters\/190","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-json\/pressbooks\/v2\/chapters"}],"about":[{"href":"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-json\/wp\/v2\/types\/chapter"}],"author":[{"embeddable":true,"href":"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-json\/wp\/v2\/users\/90"}],"version-history":[{"count":5,"href":"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-json\/pressbooks\/v2\/chapters\/190\/revisions"}],"predecessor-version":[{"id":1537,"href":"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-json\/pressbooks\/v2\/chapters\/190\/revisions\/1537"}],"part":[{"href":"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-json\/pressbooks\/v2\/parts\/150"}],"metadata":[{"href":"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-json\/pressbooks\/v2\/chapters\/190\/metadata\/"}],"wp:attachment":[{"href":"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-json\/wp\/v2\/media?parent=190"}],"wp:term":[{"taxonomy":"chapter-type","embeddable":true,"href":"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-json\/pressbooks\/v2\/chapter-type?post=190"},{"taxonomy":"contributor","embeddable":true,"href":"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-json\/wp\/v2\/contributor?post=190"},{"taxonomy":"license","embeddable":true,"href":"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-json\/wp\/v2\/license?post=190"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}